Fosamax, a popular osteoporosis drug, has been linked to a serious a serious bone disease called Osteonecrosis of the Jaw (ONJ), also known as "dead jaw" and "fossy jaw". This finding has been published in the Journal of Oral and Maxillofacial Surgeons, which prompted the US Food and Drug Administration (FDA) to review the safety of Fosamax and other drugs in its class (bisphosphonate drugs). On January 31, 2005, Merck, the manufacturer of Fosamax, received a request for data from the FDA to update the label for Fosamax to include labeling for the jawbone tissue disease. The revised label was not made available until July 2005.

If you have used Fosamax and have suffered any jaw injury or disease, contact Maloney and Campolo and have our Legal Team review your case. Please complete the contact form on the top of this page to have your Fosamax side effects case review today. Alternatively, call us at 210-922-2200 or Toll Free: 888-513-6198 to speak to our Office immediately.

About Fosamax
Fosamax (Generic: Alendronate Sodium), manufactured by Merck, gained FDA approval in 1995. Fosamax Plus D (Generic: Alendronate Sodium Cholecalciferol) contains Vitamin D. Fosamax is prescribed to treat osteoporosis and Paget's disease. Fosamax is a type of drug known as a bisphosphonate. Individuals using Fosamax or other bisphosphonate medications should attempt to steer clear of tooth extractions and other major dental work while on the drugs.

Fosamax is a Bisphosphonate
Bisphosphonate drugs are commonly used in tablet form to prevent and treat osteoporosis in post-menopausal women. Stronger forms of bisphosphonate drugs are used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can involve or metastasize to the bone, including lung cancer, breast cancer, prostate cancer, multiple myeloma, and others. When bisphosphonates are given in cancer chemotherapy, the drugs are given intravenously in higher doses and usually for longer periods of time.

About Osteonecrosis of the Jaw (ONJ)
Osteonecrosis of the Jaw (ONJ) is a condition in which the bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, causing the bone to be exposed. The exposure can eventually lead to infection and fracture and may require long-term antibiotic therapy or surgery to remove the dying bone tissue. Experts say that prevention and early treatment of patients using bisphosphonates such as Fosamax is extremely important in preserving the jawbone. Signs and symptoms of ONJ may include: jaw pain, swelling of the gums, loose teeth, drainage, exposed jaw bone, numbness, or a feeling of heaviness in the jaw. Loss of blood supply to the jaw preceeds the development of ONJ. Fosamax reduces the activity of the cells that cause bone loss, which is supposed to decrease the rapid rate of bone loss in women after menopause. However, this exact mechanism may be what causes osteonecrosis of the jawbone.

Free Consultation
If you have used Fosamax and have suffered any jaw injury or disease, contact Maloney and Campolo and have our Legal Team review your case. Please complete the contact form on the top of this page to have your Fosamax side effects case review today.

We are committed to our clients. If you or a family member has suffered a loss - call us day or night at 1-888-513-6198 or locally at 210-922-2200